共 50 条
Lipid formulations of amphotericin
被引:13
|作者:
Botero, Martha C.
[1
]
Puentes-Herrera, Marcela
[1
]
Cortes, Jorge A.
[2
]
机构:
[1] Univ Nacl Colombia, Fac Med, Dept Med Interna, Bogota, Colombia
[2] Univ Nacl Colombia, Grp Invest Enfermedades Infecciosas, Bogota, Colombia
来源:
关键词:
Amphotericin B;
fungemia;
drug toxicity;
histoplasmosis;
aspergillosis;
candidemia;
candidiasis;
invasive;
cryptococcosis;
zygomycosis;
leishmaniasis;
MULTICENTER RANDOMIZED-TRIAL;
CLINICAL-PRACTICE GUIDELINES;
INFECTIOUS-DISEASES SOCIETY;
HEMATOLOGIC MALIGNANCIES;
DOUBLE-BLIND;
VISCERAL LEISHMANIASIS;
INVASIVE ASPERGILLOSIS;
ANTIFUNGAL THERAPY;
SALVAGE THERAPY;
B AMBISOME;
D O I:
10.4067/S0716-10182014000500002
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
Amphotericin B deoxycholate use has increased during the past years in parallel with the increase in the number of immunosuppressed patients suffering invasive fungal infections. This drug is associated with a high rate of side effects, especially renal toxicity. Lipid formulations (liposomal, lipid complex, colloidal suspension and the Indian liposomal formulation) have been developed, which share the same antifungal spectrum but differ in efficacy and toxicity. A review of amphotericin lipid formulations is presented, focusing on differences in efficacy and, especially renal toxicity. The main problem for use of these formulations in Latin America is their highcost.
引用
收藏
页码:518 / 527
页数:10
相关论文